Additionally, NSCLC is particularly susceptible to interference from CH, with CH mutations potentially mistaken for tumor‐derived ctDNA, thereby complicating the interpretation of ctDNA results.[22, 36, 37] In this study, we first investigated the predictive role of tumor‐naïve ctDNA for superior survival with ICI‐chemo over chemotherapy. The gene discussed is C4B; the disease is cyclic hematopoiesis.